Biopôle Lausanne’s Post

📣 Biopôle members LASCCO SA and Abionic have announced a new licensing agreement with global #LifeSciences company Fapon. The deal will pave the way to use of the pancreatic stone protein (PSP) marker for sepsis diagnosis in China. 🧪 Since 2015, LASCCO has partnered with Abionic to develop PSP testing on high-risk patients for early diagnosis of sepsis – sometimes even before the onset of clinical symptoms. This #MedicalBreakthrough reduces the risk of organ dysfunction, improves survival rates and optimises the use of #healthcare resources. The PSP test has already been deployed in over 20 countries. Under the new agreement, Fapon will bring it to the Chinese market. 👉 Read the full story: https://lnkd.in/eSHND9XD